Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate | Zendy

Tim R. Cressey | Zendy; Oraphan Siriprakaisil | Zendy; Rachel W. Kubiak | Zendy; Virat Klinbuayaem | Zendy; Pra-ornsuda Sukrakanchana | Zendy; Justice QuameAmaglo | Zendy; Hideaki Okochi | Zendy; Yardpiroon Tawon | Zendy; Ratchada Cressey | Zendy; Jared M. Baeten | Zendy; Monica Gandhi | Zendy; Paul K. Drain | Zendy

Open Access

Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate

Author(s) -

Tim R. Cressey,

Oraphan Siriprakaisil,

Rachel W. Kubiak,

Virat Klinbuayaem,

Pra-ornsuda Sukrakanchana,

Justice QuameAmaglo,

Hideaki Okochi,

Yardpiroon Tawon,

Ratchada Cressey,

Jared M. Baeten,

Monica Gandhi,

Paul K. Drain

Publication year - 2020

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2020.06.037

Subject(s) - pharmacokinetics , urine , dosing , medicine , urinary system , tenofovir , ingestion , emtricitabine , crossover study , pharmacology , placebo , antiretroviral therapy , human immunodeficiency virus (hiv) , viral load , alternative medicine , family medicine , pathology

The aim was to fully characterize the plasma and urine washout pharmacokinetics of tenofovir (TFV) in adults following 6 weeks of controlled levels of tenofovir disoproxil fumarate (TDF) adherence, in order to inform the utility of clinic-based adherence testing.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research